GlassScriptPhysician profile
Roxene C Turner
NPI 1629082193
$1,088.67
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $942 · 2022: $21.96 · 2023: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $120.02 | 2021 | |
| Atricure, INC. | $110.14 | 2021 | |
| Beigene USA, INC. | $106.57 | 2023 | Brukinsa |
| Dexcom, INC. | $81.97 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $79.67 | 2021 | |
| Abbott Laboratories | $77.50 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $74.90 | 2021 | |
| Lilly USA, LLC | $71.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $57.55 | 2021 | |
| Esperion Therapeutics, INC. | $50.62 | 2021 | |
| Abbvie INC. | $44.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.83 | 2021 | |
| Amneal Pharmaceuticals LLC | $39.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.33 | 2021 | |
| Insulet Corporation | $23.65 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.08 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2021 | |
| Clarus Therapeutics INC. | $14.08 | 2021 | |
| Eisai INC. | $13.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.42 | 2021 | |
| Amarin Pharma, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxene Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.